CoChat

Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis

Open access
Liu, Dan, Jin, Biao, Chen, Wei, Yun, Peng · 2019 · BMC Pharmacology and Toxicology

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Dipeptidyl peptidase 4 (DPP-4) inhibitors are newer oral anti-diabetic agents which have been approved by the Food and Drug Administration for the treatment of patients with type 2 diabetes mellitus (T2DM). In this analysis, we aimed to systematically compare the cardiovascular outcomes associated with DPP-4 inhibitors versus non-DPP-4 inhibitor users. METHODS: All English publications that compared the use of DPP-4 inhibitors and that reported cardiovascular outcomes in patients with T2DM were searched using specific terms. Studies were included if they satisfied the following inclusion criteria: They were randomized trials or observation cohorts/registries comparing DPP-4 inhibitors use in patients with T2DM; The studies included a large sample size of participants; And they reported cardiovascular outcomes as their main endpoints. RevMan 5.3 was used to analyze the data, and odds ratios (OR) with 95% confidence intervals (CI) were used to represent the results. RESULTS: A total number of 157,478 participants with T2DM were included. Seventy-six thousand and twenty six patients were assigned to the DPP-4 inhibitor group whereas 81,452 patients were assigned to the control group. Results of the current analysis showed that during a mean follow-up time period ranging from 52 to 152 weeks, the primary endpoint (cardiovascular death/non-fatal myocardial infarction (MI)/non-fatal stroke) was not significantly different in the treatment of T2DM patients with versus without DPP-4 inhibitors (OR: 0.95, 95% CI: 0.86-1.04; P = 0.26). Cardiovascular death (OR: 1.00, 95% CI: 0.90-1.10; P = 0.93), stroke (OR: 1.03, 95% CI: 0.89-1.18; P = 0.72), MI (OR: 0.97, 95% CI: 0.88-1.07; P = 0.59), all-cause mortality (OR: 0.84, 95% CI: 0.59-1.18; P = 0.31), hospitalization for cardiovascular complications (OR: 1.02, 95% CI: 0.96-1.09; P = 0.45) and hospitalization specifically for heart failure (OR: 1.05, 95% CI: 0.90-1.23; P = 0.55) were also similarly manifested in both groups. CONCLUSION: The current analysis showed that treatment with DPP-4 inhibitors did not significantly increase cardiovascular outcomes in these patients with T2DM indicating that those drugs might be safe to use in terms of cardiovascular events.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40360-019-0293-y

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flow diagram showing the study selection
Fig. 1 Flow diagram showing the study selectionCC BY · PubMed Central
Fig. 2 Cardiovascular outcomes observed with DPP-4 inhibitor users versus the control group (part 1)
Fig. 2 Cardiovascular outcomes observed with DPP-4 inhibitor users versus the control group (part 1)CC BY · PubMed Central
Fig. 3 Cardiovascular outcomes observed with DPP-4 inhibitor users versus the control group (part 2)
Fig. 3 Cardiovascular outcomes observed with DPP-4 inhibitor users versus the control group (part 2)CC BY · PubMed Central
Fig. 4 Funnel plot representing publication bias
Fig. 4 Funnel plot representing publication biasCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 56

Metadata

Authors
Liu, D., Jin, B., Chen, W., & Yun, P.
Affiliations
First People's Hospital of Jingzhou (CN)
Corresponding author
Liu, Dan
Venue
BMC Pharmacology and Toxicology
Published
2019-03-04
Volume
20
Issue
1
Pages
15-15
ISSN
2050-6511 (ISSN-L)
OpenAlex
W2918566284
Cited by
56
References
16
Citations by year
2026: 4 · 2025: 9 · 2024: 9 · 2023: 7 · 2022: 6 · 2021: 11 · 2020: 8 · 2019: 1
FWCI
1.00
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0/ (tdm)
Locations
  • BMC Pharmacology and Toxicology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
DPP-4 inhibitors, type 2 diabetes, cardiovascular outcomes, cardiovascular mortality, myocardial infarction, stroke, all-cause mortality, cardiovascular hospitalization, oral antidiabetic drugs, comparative effectiveness, cardiovascular safety, glycemic control, HbA1c, LDL cholesterol, blood pressure, body mass index, cardiovascular risk factors, cardiovascular risk stratification
MeSH terms
Cardiovascular Diseases, Diabetes Mellitus, Type 2, Odds Ratio, Randomized Controlled Trials as Topic, Dipeptidyl-Peptidase IV Inhibitors, Observational Studies as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1186/s40360-019-0293-y
The paper
Liu, D., Jin, B., Chen, W., & Yun, P. (2019). Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis. BMC Pharmacology and Toxicology. https://doi.org/10.1186/s40360-019-0293-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.